Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zentalis Pharmaceuticals Q3 2026 Results: Net Loss of $28.8M, Loss Widens

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, azenosertib (ZN-c3), for various oncology indications including ovarian cancer. As of November 4, 2026, the company had 98,265,863 shares of common stock outstanding and is prioritizing its Phase 3 ASPENOVA and Phase 2 DENALI trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-28.7-26.7
Net income-28.8-26.7
EPS (diluted, $ a share)$-0.34$-0.37

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ZNTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zentalis Pharmaceuticals, Inc.: key numbers

Share price
$1.49Close, Nov 17
Market cap
$146M
Shares outstanding
98.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zentalis Pharmaceuticals, Inc.

All →
4:10 PM ET 8-K
Financial Results

Zentalis Pharmaceuticals Financial Results

Zentalis Pharmaceuticals reported third quarter 2026 financial results and provided updates on its clinical pipeline, specifically the azenosertib program for ovarian cancer. The company expects a topline readout from the DENALI trial in the first half of 2027 and reported a cash runway extending into the first half of 2028.

“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals

“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.